EPHA10 and breast cancer: Additionally, Taki et al. crafted a dimeric bispecific antibody binding both EPHA10 and CD3, which incited an anticancer immune response by stimulating T cells to kill EPHA10-overexpressing BC cells both in vitro and in vivo [27].